SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity through B Cell Antigen Presentation
Source abstract
Abstract
Current neoantigen cancer vaccines activate T cell immunity through dendritic cell/macrophage-mediated antigen presentation. It is unclear whether incorporating B cell-mediated antigen presentation into current neoantigen vaccines could enhance CD4/CD8 T cell immunity to improve their anticancer efficacy. We developed SARS-CoV-2 B cell epitope-guided neoantigen peptide/mRNA cancer nanovaccines (B SARS T NeoAg Vax) to improve anticancer efficacy by enhancing tumor-specific CD4/CD8 T cell antitumor immunity through B cell-mediated antigen presentation. B SARS T NeoAg Vax cross-linked with B cell receptor, promoted SARS-CoV-2 B cell-mediated antigen presentation to tumor-specific CD4 T cells, increased tumor-specific follicular/nonfollicular CD4 T cells, and enhanced B cell-dependent tumor-specific CD8 T cell immunity. B SARS T NeoAg Vax achieved superior efficacy in melanoma, pancreatic, and breast cancer models compared with the current neoantigen vaccines. Our study provides a universal platform, SARS-CoV-2 B epitope-guided neoantigen nanovaccines, to improve anticancer efficacy against various cancer types by enhancing CD4/CD8 T cell antitumor immunity through viral-specific B cell-mediated antigen presentation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · T-cell and B-cell Immunology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Sciences, College of Pharmacy
University of Michigan
Department of Pharmacology and Pharmaceutical Science, College of Pharmacy
The University of Houston
Funding
National Institutes of Health
References (100+)
Show source-provided references
1. 10.1038/nature2299110.1038/nature22991 ↗
2. 10.1038/s41591-020-01206-410.1038/s41591-020-01206-4 ↗
3. 10.1016/S0140-6736(23)02268-710.1016/S0140-6736(23)02268-7 ↗
4. 10.1038/s41586-023-06063-y10.1038/s41586-023-06063-y ↗
5. 10.1038/nm.310510.1038/nm.3105 ↗
6. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
7. 10.1016/j.coi.2015.05.00410.1016/j.coi.2015.05.004 ↗
8. 10.1101/cshperspect.a03370410.1101/cshperspect.a033704 ↗
9. 10.1101/cshperspect.a02882910.1101/cshperspect.a028829 ↗
10. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
11. 10.1038/s41541-019-0103-y10.1038/s41541-019-0103-y ↗
12. 10.1186/s13045-019-0787-510.1186/s13045-019-0787-5 ↗
13. 10.1016/j.cell.2022.06.03510.1016/j.cell.2022.06.035 ↗
14. 10.1146/annurev-med-050217-12190010.1146/annurev-med-050217-121900 ↗
15. 10.1038/s41571-020-00460-210.1038/s41571-020-00460-2 ↗
16. 10.1101/cshperspect.a02891010.1101/cshperspect.a028910 ↗
17. 10.1038/nature2300310.1038/nature23003 ↗
18. 10.1038/s41591-024-02894-y10.1038/s41591-024-02894-y ↗
19. 10.7150/ntno.1979610.7150/ntno.19796 ↗
20. 10.1038/nri286810.1038/nri2868 ↗
21. 10.1586/14760584.7.1.4310.1586/14760584.7.1.43 ↗
22. 10.7150/ntno.2172310.7150/ntno.21723 ↗
23. 10.1038/nri237910.1038/nri2379 ↗
24. 10.1038/s41568-022-00466-110.1038/s41568-022-00466-1 ↗
25. 10.1038/nri245410.1038/nri2454 ↗
26. 10.1093/intimm/13.12.158310.1093/intimm/13.12.1583 ↗
27. 10.1016/j.trecan.2016.10.01010.1016/j.trecan.2016.10.010 ↗
28. 10.1038/nm0598-62710.1038/nm0598-627 ↗
29. 10.1002/ijc.2117710.1002/ijc.21177 ↗
30. 10.4049/jimmunol.121.1.35910.4049/jimmunol.121.1.359 ↗
31. 10.1007/PL0000667210.1007/PL00006672 ↗
32. 10.1038/nri385710.1038/nri3857 ↗
33. 10.4049/jimmunol.090300910.4049/jimmunol.0903009 ↗
34. 10.1080/2162402X.2021.187358510.1080/2162402X.2021.1873585 ↗
35. 10.1016/j.ccr.2005.04.01410.1016/j.ccr.2005.04.014 ↗
36. 10.1158/2326-6066.CIR-20-094910.1158/2326-6066.CIR-20-0949 ↗
37. 10.1158/1078-0432.CCR-12-023410.1158/1078-0432.CCR-12-0234 ↗
38. 10.1038/s41586-019-1914-810.1038/s41586-019-1914-8 ↗
39. 10.18632/oncotarget.170110.18632/oncotarget.1701 ↗
40. 10.1016/j.cell.2020.02.01510.1016/j.cell.2020.02.015 ↗
41. 10.1080/2162402X.2018.151245810.1080/2162402X.2018.1512458 ↗
42. 10.1080/2162402X.2018.153529310.1080/2162402X.2018.1535293 ↗
43. 10.1186/s40425-019-0726-610.1186/s40425-019-0726-6 ↗
44. 10.3892/ijo.2020.504210.3892/ijo.2020.5042 ↗
45. 10.1038/s41586-019-1922-810.1038/s41586-019-1922-8 ↗
46. 10.1038/s41586-019-1906-810.1038/s41586-019-1906-8 ↗
47. 10.1158/1078-0432.CCR-15-276210.1158/1078-0432.CCR-15-2762 ↗
48. 10.1172/jci.insight.12964110.1172/jci.insight.129641 ↗
49. 10.1016/j.cell.2019.10.02810.1016/j.cell.2019.10.028 ↗
50. 10.1016/j.immuni.2018.08.01210.1016/j.immuni.2018.08.012 ↗
51. 10.4049/jimmunol.160185210.4049/jimmunol.1601852 ↗
52. 10.1016/j.ccell.2023.02.01710.1016/j.ccell.2023.02.017 ↗
53. 10.1038/s41587-022-01547-010.1038/s41587-022-01547-0 ↗
54. 10.1038/s41577-023-00937-y10.1038/s41577-023-00937-y ↗
55. 10.1021/acsnano.3c1303810.1021/acsnano.3c13038 ↗
56. 10.2217/fon-2020-022410.2217/fon-2020-0224 ↗
57. 10.3748/wjg.v24.i48.541810.3748/wjg.v24.i48.5418 ↗
58. 10.1021/acs.accounts.0c0045610.1021/acs.accounts.0c00456 ↗
59. 10.1016/j.cell.2021.11.00710.1016/j.cell.2021.11.007 ↗
60. 10.1146/annurev.iy.11.040193.00155510.1146/annurev.iy.11.040193.001555 ↗
61. 10.1007/s00005-008-0014-510.1007/s00005-008-0014-5 ↗
62. 10.1016/j.coi.2004.03.00710.1016/j.coi.2004.03.007 ↗
63. 10.1038/s41467-022-32811-110.1038/s41467-022-32811-1 ↗
64. 10.1038/nature1442610.1038/nature14426 ↗
65. 10.1016/j.ebiom.2020.10291110.1016/j.ebiom.2020.102911 ↗
66. 10.1158/1078-0432.CCR-17-280710.1158/1078-0432.CCR-17-2807 ↗
67. 10.1021/acsami.5b0199110.1021/acsami.5b01991 ↗
68. 10.1039/C3TB21338B10.1039/C3TB21338B ↗
69. 10.1016/j.immuni.2021.06.01810.1016/j.immuni.2021.06.018 ↗
70. 10.1371/journal.pone.018699810.1371/journal.pone.0186998 ↗
71. 10.1016/j.immuni.2022.02.00110.1016/j.immuni.2022.02.001 ↗
72. 10.1016/j.immuni.2021.11.00310.1016/j.immuni.2021.11.003 ↗
73. 10.1038/s41571-022-00619-z10.1038/s41571-022-00619-z ↗
74. 10.1016/j.smim.2022.10170310.1016/j.smim.2022.101703 ↗
75. 10.1038/s41586-021-03704-y10.1038/s41586-021-03704-y ↗
76. 10.1158/2326-6066.CIR-17-007510.1158/2326-6066.CIR-17-0075 ↗
77. 10.1126/sciimmunol.abn585910.1126/sciimmunol.abn5859 ↗
78. 10.1038/nri149810.1038/nri1498 ↗
79. 10.1172/JCI3142210.1172/JCI31422 ↗
80. 10.1038/s41591-022-01821-310.1038/s41591-022-01821-3 ↗
81. 10.1038/s41586-020-03144-010.1038/s41586-020-03144-0 ↗
82. 10.1016/j.cell.2022.02.01210.1016/j.cell.2022.02.012 ↗
83. 10.1158/0008-5472.CAN-21-237610.1158/0008-5472.CAN-21-2376 ↗
84. 10.1038/s41586-023-06231-010.1038/s41586-023-06231-0 ↗
85. 10.1016/j.cell.2020.05.01710.1016/j.cell.2020.05.017 ↗
86. 10.1016/j.immuni.2005.02.00310.1016/j.immuni.2005.02.003 ↗
87. 10.1038/s41586-020-2611-310.1038/s41586-020-2611-3 ↗
88. 10.1038/s41586-020-2931-310.1038/s41586-020-2931-3 ↗
89. 10.1016/j.immuni.2021.12.00710.1016/j.immuni.2021.12.007 ↗
90. 10.1084/jem.186.1.6510.1084/jem.186.1.65 ↗
91. 10.1038/3099610.1038/30996 ↗
92. 10.1038/3100210.1038/31002 ↗
93. 10.1126/science.107261510.1126/science.1072615 ↗
94. 10.1038/nature0333710.1038/nature03337 ↗
95. 10.1007/s00262-008-0599-x10.1007/s00262-008-0599-x ↗
96. 10.1016/j.immuni.2018.06.00610.1016/j.immuni.2018.06.006 ↗
97. 10.1016/S0022-1759(98)00204-X10.1016/S0022-1759(98)00204-X ↗
98. 10.1126/scitranslmed.abl364910.1126/scitranslmed.abl3649 ↗
99. 10.1021/acsami.8b0283010.1021/acsami.8b02830 ↗
100. 10.1126/science.178.4063.87110.1126/science.178.4063.871 ↗